Noticias de VIR_US

Noticias del mercado

Últimas noticias sobre VIR_US — 103 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: VIR_US ✕ 103 resultados
23/02/2026 VIR_US — Stocktwits ES ← EN
¿Por qué las acciones de Vir Biotechnology aumentaron un 60% hoy fuera de horario?
23/02/2026 VIR_US — Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
23/02/2026 VIR_US — TradingView
Vir Biotechnology, Inc. SEC 10-K Report
23/02/2026 VIR_US — ChartMill
Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates
23/02/2026 VIR_US — Yahoo Finance
Vir Biotechnology Q4 Earnings Call Highlights
23/02/2026 VIR_US — Investing.com
Earnings call transcript: Vir Biotechnology beats Q4 2025 earnings expectations
23/02/2026 VIR_US — Business Wire
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN
23/02/2026 VIR_US — Yahoo Finance ES ← EN
Astellas y Vir Biotechnology anuncian una colaboración estratégica global para avanzar en el PRO-XTEN® T-Cell Engager VIR-5500 de doble máscara dirigido a PSMA para el tratamiento del cáncer de próstata
23/02/2026 VIR_US — PR Newswire
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
23/02/2026 VIR_US — Yahoo Finance
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
23/02/2026 VIR_US — Stock Titan
Experimental prostate cancer T-cell therapy gets $335M boost from Astellas
23/02/2026 VIR_US — marketscreener.com
Earnings Flash (VIR) Vir Biotechnology, Inc. Reports Q4 Revenue $64.1M
23/02/2026 VIR_US — Investing.com
Vir Biotechnology reports phase 1 trial results for VIR-5500
23/02/2026 VIR_US — marketscreener.com ES ← EN
Astellas Pharma Inc. y Vir Biotechnology, Inc. anuncian una colaboración estratégica global para avanzar en el PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 dirigido a PSMA para el tratamiento del cáncer de próstata

Astellas Pharma Inc. y Vir Biotechnology, Inc. anuncian una colaboración estratégica global para avanzar en el PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 dirigido a PSMA para el tratamiento del cáncer de…

23/02/2026 VIR_US — GuruFocus
Vir Biotechnology (VIR) Announces Strategic Collaboration with A
23/02/2026 VIR_US — Seeking Alpha
Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset (VIR:NASDAQ)
23/02/2026 VIR_US — Reuters
Astellas collaborates with Vir to develop its experimental prostate cancer drug
23/02/2026 VIR_US — TradingView
Vir Biotechnology, Astellas Ink VIR-5500 Collaboration; Astellas Invests $75M at 50% Premium
20/02/2026 VIR_US — TradingView
Vir Biotechnology Inc expected to post a loss of 49 cents a share - Earnings Preview
14/02/2026 VIR_US — Stock Titan ES ← EN
VIR Financials: estado de resultados, balance y flujo de caja

Página 5 de 6

keyboard_arrow_up